MHRA's Rx-Only Stance: Clarifying CBD Prescriptions in UK Cannabis

A persistent query amongst nascent cannabis clinics and dispensing pharmacies in the UK has revolved around the dispensing requirements for cannabidiol (CBD) preparations. While CBD products sold as food supplements or cosmetics fall under distinct regulatory frameworks (e.g., FSA Novel Foods, UK REACH), their entry into the medicinal sphere introduces a higher degree of scrutiny.

Recent implicit and explicit communications from the MHRA have underscored a foundational principle: if a CBD containing product is being prescribed as a medicine, it is unequivocally a prescription-only medicine (POM) and must be dispensed accordingly. This isn't a new rule, but rather a recent and forceful clarification of existing legislation, notably the Human Medicines Regulations 2012 (HMRs).

The Human Medicines Regulations 2012 and CBD

The HMRs specify multiple classifications for medicines, including Prescription Only Medicines (POM), Pharmacy Medicines (P), and General Sales List (GSL). For a product to be classified as anything other than POM, it must meet specific criteria, often relating to safety, mode of action, and potential for misuse. Crucially, any substance controlled under the Misuse of Drugs Regulations 2001 (such as THC, even at trace levels) automatically defaults to POM status if it is a medicine.

Even for products containing only CBD, where the CBD itself is not a controlled substance, if they are manufactured, imported, and prescribed with a medicinal claim or for a medicinal purpose, they fall under the HMRs. The MHRA’s position is clear: in the absence of a specific GSL or P classification granted for a CBD product, its status when prescribed is POM. Claims of 'special' status or interpretations of regulatory grey areas for CBD-only products, particularly those implying dispensing flexibility, are being disabused.

Practical Implications for Clinics and Pharmacies

For UK medicinal cannabis clinics, this means ensuring that all CBD-only medicinal products prescribed (whether as isolates, broad-spectrum, or full-spectrum with permitted trace THC) are treated with the same dispensing rigour as any other POM. This entails:

  • Valid Prescriptions: Ensuring every dispense is against a legitimate, signed prescription from a registered medical practitioner.
  • Pharmacist Oversight: Dispensing by or under the direct supervision of a registered pharmacist.
  • GxP Compliance: Adherence to Good Dispensing Practice (GDP) and other relevant GxP principles throughout the supply chain and dispensing process.
  • Record Keeping: Meticulous record-keeping as required for POMs, including patient details, prescribing doctor, and product batch information.

Any attempt to circumvent this – for instance, by treating CBD-only medicinal products as akin to food supplements or attempting to sell them directly without a prescription from a pharmacy – poses a significant regulatory risk. The MHRA has demonstrated its willingness to act on non-compliance, with potential consequences ranging from warnings and remedial action to licence suspension or revocation.

The Home Office and ACMD Position

While the MHRA focuses on the medicinal product aspect, the Home Office remains the gatekeeper for controlled drugs. The Advisory Council on the Misuse of Drugs (ACMD) has previously opined on CBD, clarifying its non-controlled status in pure form. However, the Home Office’s licensing requirements for activities involving even trace THC in cannabis-based products for medicinal use (CBPMs) still apply, ensuring a tightly controlled supply chain. This reinforces the necessity for robust licensing from both the Home Office (where applicable) and the MHRA for manufacturing, importation, and distribution of these products.

Board-Level Takeaway: Mitigating Risk

Boards overseeing UK medicinal cannabis operations must ensure their internal policies and procedures explicitly align with this reinforced MHRA stance. Presumption of compliance, or reliance on ambiguous interpretations, is no longer tenable. Due diligence extends to understanding the exact regulatory classification of every product dispensed and ensuring robust operational frameworks are in place to meet POM requirements. The cost of non-compliance, both financial and reputational, far outweighs the perceived benefits of short-cutting established medicinal product regulations. Clear training, regular audits, and proactive engagement with regulatory requirements are paramount.